Non-steroidal anti-inflammatory drugs and cancer incidence by sex in the VITamins and Lifestyle (VITAL) cohort

Cancer Causes and Control

Volumn 23, Issue 3, 2012, Pages 431-444

  Brasky, Theodore M ^a,b   Potter, John D ^a,b   Kristal, Alan R ^a,b   Patterson, Ruth E ^c   Peters, Ulrike ^a,b   Asgari, Maryam M ^c,d   Thornquist, Mark D ^a,b   White, Emily ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d DIVISION OF RESEARCH   (United States)

Author keywords

Aspirin; Ibuprofen; Non steroidal anti inflammatory drugs; Total cancer

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; IBUPROFEN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER INCIDENCE; CANCER INVASION; CANCER LOCALIZATION; CANCER RISK; COHORT ANALYSIS; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUESTIONNAIRE; RISK REDUCTION; SEX DIFFERENCE; SOLID TUMOR; UNITED STATES;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLORECTAL NEOPLASMS; CONFIDENCE INTERVALS; FEMALE; HUMANS; IBUPROFEN; INCIDENCE; LIFE STYLE; MALE; MIDDLE AGED; NEOPLASMS; ODDS RATIO; PROSPECTIVE STUDIES; QUESTIONNAIRES; RISK FACTORS; SEX FACTORS; TIME FACTORS; WASHINGTON;

EID: 84862499885     PISSN: 09575243     EISSN: 15737225     Source Type: Journal    
DOI: 10.1007/s10552-011-9891-8     Document Type: Article

References (38)

1. Harris RE, Beebe-Donk J, Doss H, Burr Doss D (2005) Aspirin, ibuprofen, and other non-steroidal anti-inflammatory drugs in cancer prevention: a critical review of non-selective COX-2 blockade (review). Oncol Rep 13:559-583
2. Rothwell PM, Fowkes FG, Belch JF, Ogawa H, Warlow CP, Meade TW (2011) Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 377:31-41
3. Cook NR, Lee IM, Gaziano JM et al (2005) Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. JAMA 294:47-55 (Pubitemid 41002838)
4. Jacobs EJ, Thun MJ, Bain EB, Rodriguez C, Henley SJ, Calle EE (2007) A large cohort study of long-term daily use of adultstrength aspirin and cancer incidence. J Natl Cancer Inst 99:608-615 (Pubitemid 47073542)
5. Bardia A, Ebbert JO, Vierkant RA et al (2007) Association of aspirin and nonaspirin nonsteroidal anti-inflammatory drugs with cancer incidence and mortality. J Natl Cancer Inst 99:881-889 (Pubitemid 47073510)
6. Sorensen HT, Friis S, Norgard B et al (2003) Risk of cancer in a large cohort of nonaspirin NSAID users: a population-based study. Br J Cancer 88:1687-1692 (Pubitemid 36760410)
7. Schreinemachers DM, Everson RB (1994) Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology 5:138-146 (Pubitemid 24073387)
8. Friis S, Sorensen HT, McLaughlin JK, Johnsen SP, Blot WJ, Olsen JH (2003) A population-based cohort study of the risk of colorectal and other cancers among users of low-dose aspirin. Br J Cancer 88:684-688 (Pubitemid 36411444)
9. White E, Patterson RE, Kristal AR et al (2004) VITamins And Lifestyle cohort study: study design and characteristics of supplement users. Am J Epidemiol 159:83-93 (Pubitemid 38049425)
10. Kim MA, Kim CJ, Seo JB et al (2011) The effect of aspirin on C-reactive protein in hypertensive patients. Clin Exp Hypertens 33:47-52
11. Menzies D, Nair A, Meldrum KT, Hopkinson P, Lipworth BJ (2008) Effect of aspirin on airway inflammation and pulmonary function in patients with persistent asthma. J Allergy Clin Immunol 121:1184-1189
12. Littman AJ, Kristal AR, White E (2006) Recreational physical activity and prostate cancer risk (United States). Cancer Causes Control 17:831-841
13. WCRF/AICR (2007) Food, nutrition and the prevention of cancer: a global perspective. AICR, Washington
14. Danesh J, Wheeler JG, Hirschfield GM et al (2004) C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. New Engl J Med 350: 1387-1397 (Pubitemid 38419992)
15. Pierce BL, Neuhouser ML, Wener MH et al (2009) Correlates of circulating C-reactive protein and serum amyloid A concentrations in breast cancer survivors. Breast Cancer Res Treat 114: 155-167
16. Koenig W, Sund M, Frohlich M, Lowel H, Hutchinson WL, Pepys MB (2003) Refinement of the association of serum C-reactive protein concentration and coronary heart disease risk by correction for within-subject variation over time: the MONICA Augsburg studies, 1984 and 1987. Am J Epidemiol 158: 357-364 (Pubitemid 41288803)
17. Bielecka-Dabrowa A, Goch JH, Mikhailidis DP, Rysz J, Maciejewski M, Banach M (2009) The influence of atorvastatin on parameters of inflammation and function of the left ventricle in patients with dilated cardiomyopathy. Med Sci Monit 15:MS12-MS23
18. Harris NL, Jaffe ES, Diebold J et al (1999) The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997. Ann Oncol 10:1419-1432 (Pubitemid 30017051)
19. Harris NL, Jaffe ES, Diebold J et al (1999) World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 17:3835-3849
20. Rothwell PM, Wilson M, Elwin CE et al (2010) Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet 376:1741-1750
21. Cole BF, Logan RF, Halabi S et al (2009) Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials. J Natl Cancer Inst 101:256-266
22. Ready A, Velicer CM, McTiernan A, White E (2008) NSAID use and breast cancer risk in the VITAL cohort. Breast Cancer Res Treat 109:533-543 (Pubitemid 351692052)
23. Brasky TM, Velicer CM, Kristal AR, Peters U, Potter JD, White E (2010) Nonsteroidal anti-inflammatory drugs and prostate cancer risk in the VITamins And Lifestyle (VITAL) cohort. Cancer Epidemiol Biomarkers Prev 19:3185-3188
24. Slatore CG, Au DH, Littman AJ, Satia JA, White E (2009) Association of nonsteroidal anti-inflammatory drugs with lung cancer: results from a large cohort study. Cancer Epidemiol Biomarkers Prev 18:1203-1207
25. Asgari MM, Maruti SS, White E (2008) A large cohort study of nonsteroidal anti-inflammatory drug use and melanoma incidence. J Natl Cancer Inst 100:967-971 (Pubitemid 351957509)
26. Walter RB, Milano F, Brasky TM, White E (2011, in press) Long-term use of acetaminophen, aspirin, and other non-steroidal anti-inflammatory drugs and risk of hematologic malignancies: results from the prospective VITamins And Lifestyle (VITAL) study. J Clin Oncol 29(17):2424-2431
27. Chan AT, Giovannucci EL, Meyerhardt JA, Schernhammer ES, Curhan GC, Fuchs CS (2005) Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer. JAMA 294:914-923 (Pubitemid 41215460)
28. Takkouche B, Regueira-Mendez C, Etminan M (2008) Breast cancer and use of nonsteroidal anti-inflammatory drugs: a meta-analysis. J Natl Cancer Inst 100:1420-1423
29. Bonovas S, Filioussi K, Sitaras NM (2005) Do nonsteroidal antiinflammatory drugs affect the risk of developing ovarian cancer? A meta-analysis. Br J Clin Pharmacol 60:194-203 (Pubitemid 41075905)
30. Khuder SA, Herial NA, Mutgi AB, Federman DJ (2005) Non-steroidal antiinflammatory drug use and lung cancer: a meta-analysis. Chest 127:748-754 (Pubitemid 40775501)
31. Gonzalez-Perez A, Garcia Rodriguez LA, Lopez-Ridaura R (2003) Effects of non-steroidal anti-inflammatory drugs on cancer sites other than the colon and rectum: a meta-analysis. BMC Cancer 3:28
32. Cerhan JR, Anderson KE, Janney CA, Vachon CM, Witzig TE, Habermann TM (2003) Association of aspirin and other non-steroidal anti-inflammatory drug use with incidence of non- Hodgkin lymphoma. Int J Cancer 106:784-788 (Pubitemid 36993403)
33. Baker JA, Weiss JR, Czuczman MS, Menezes RJ, Ambrosone CB, Moysich KB (2005) Regular use of aspirin or acetaminophen and risk of non-Hodgkin lymphoma. Cancer Causes Control 16:301-308 (Pubitemid 40897849)
34. Baigent C, Blackwell L, Collins R et al (2009) Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 373:1849-1860
35. Adelman EE, Lisabeth L, Brown DL (2011) Gender differences in the primary prevention of stroke with aspirin. Women's Health (London, England) 7:341-352; quiz 52-3
36. Berger JS, Roncaglioni MC, Avanzini F, Pangrazzi I, Tognoni G, Brown DL (2006) Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA 295:306-313
37. Navarro SL, Saracino MR, Makar KW et al (2011) Determinants of aspirin metabolism in healthy men and women: effects of dietary inducers of UDP-glucuronosyltransferases. J Nutrigenet Nutrigenomics 4:110-118
38. Waxman DJ, Holloway MG (2009) Sex differences in the expression of hepatic drug metabolizing enzymes. Mol Pharmacol 76:215-228